AMED has a market capitalization of $9,938,312,263 -- more than approximately 82.46% of US stocks.
AMED's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 571.54 -- higher than 93.32% of US-listed equities with positive expected earnings growth.
The price/operating cash flow metric for Amedisys Inc is higher than 85.54% of stocks in our set with a positive cash flow.
If you're looking for stocks that are quantitatively similar to Amedisys Inc, a group of peers worth examining would be ATR, JHG, EHC, MORN, and BKI.
Amedisys provides home health and hospice care services. It operates through two segments, Home Health and Hospice. The company was founded in 1982 and is based in Baton Rouge, Louisiana.
AMED Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Amedisys Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Amedisys Inc ranked in the 47th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for AMED, they are:
Interest coverage, a measure of earnings relative to interest payments, is 16.91; that's higher than 78.63% of US stocks in the Healthcare sector that have positive free cash flow.
The business' balance sheet reveals debt to be 4% of the company's capital (with equity being the remaining amount). Approximately merely 14.94% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
AMED's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 44.96% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as AMED, try BDX, FGEN, IQV, INBP, and PAHC.